SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Robert S. who wrote (8388)1/20/1999 10:26:00 AM
From: aknahow  Read Replies (2) | Respond to of 17367
 
Robert_S, as far as a fair observer would be concerned, I have answered the question asked by Opala. Martin at Xoma was the trigger and I had indicated that I posted immediately and referred to the slgonzalez post, the slgonzalez and my post answered the, "what". Some had trouble believing the what since it did not seem logical. The, "what", was repeated several times. Several people made direct recommendations to call XOMA. With your memory and interest in reposting historical post, I am sure you could repost at least 3 older post of Martin telling S.I. posters to call her when they have questions.

Second, I think opalapril is quite capable of objecting to my response to his question, directly and whenever he feels it necessary. Far from being haughty, I tried several times, after swearing not to go into it again to explain not only what was said but how what was said fit into what was said in the past. I wanted to move on because I had nothing more to add.




To: Robert S. who wrote (8388)1/20/1999 10:45:00 AM
From: Tharos  Respond to of 17367
 
Your assumption that everyone automatically posts 100% of everything they know or find is probably not a good one. George, Biostock1, RobertK and I are not privy to any particularly special news but we do spend time searching, researching, and talking with the company. Investor Relations is a touchy area that can open a company up to investor law suits, should someone perceive a person or persons are getting special favor or "insider knowledge." I am certain this is not the case with Xoma, but it has been said many times that your answers lie in calling Ellen at Xoma. That you chose to attack one of the regular information providers vice calling Ellen just reinforces my premise that the contents of your cranium and the contents of your bowels are similar.

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Investor Relations Hotline
For inquiries from shareholders, investors, brokers, analysts and the media:
Call Ellen Martin at (800) BIO-XOMA (246-9662) or email InvestorRelations@xoma.com

Got it bobby?



To: Robert S. who wrote (8388)1/20/1999 4:58:00 PM
From: Cacaito  Read Replies (3) | Respond to of 17367
 
ncbi.nlm.nih.gov

Japanese review mentioned Bpi as "potential".